Active ingredientCopanlisibCat. No. P-C247-001CAS 1032568-63-0Family · Pharmaceutical analytical standards
Copanlisib
An intravenous inhibitor of phosphatidylinositol 3-kinase (PI3K), active mainly on the alpha and delta isoforms found in malignant B cells: granted accelerated approval in the United States in 2017 for relapsed follicular lymphoma, it was withdrawn from the US market in 2023. This family brings together the active ingredient, metabolites and other impurities.
Did you know?It is given by intravenous infusion and stays in the body a long time: its average half-life is about 39 hours, but in some people it exceeds 80.
Go to the active ingredient →Active ingredientCopanlisibCat. No. P-C247-001CAS 1032568-63-0
MetaboliteCopanlisib M1 MetaboliteCat. No. P-C247-002
ImpurityCopanlisib Impurity 1Cat. No. P-C247-003CAS 1919065-44-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.